Paramyxoviridae Infections
5
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Rhpiv3cp45
Research Leaders
16 sponsors active, led by Johns Hopkins Bloomberg School of Public Health
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (5)
The Respiratory Protection Effectiveness Clinical Trial
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults
Surveillance Study of Viral Infections Following Lung Transplantation
Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants
Research Network
Common Treatments
- Rhpiv3cp452
- N95 Respirator1
- Medicalsurgical Mask1
- Rbhpiv31
Active Sponsors
- Johns Hopkins Bloomberg School of Public Health3
- National Institute of Allergy and Infectious Diseases (NIAID)3
- Department of Pulmonology1
- VA St. Louis Health Care System1
- Children's Hospital Colorado1
Top Investigators
Johns Hopkins Bloomberg School of Public Health
New York Harbor Healthcare System VA
UTSouthwestern Medical Center
Johns Hopkins University
CDC-NIOSH
Related Conditions
- Virus Diseases3
- Rhinovirus1
- Respiratory Syncytial Viruses1
- Influenza1
- Bronchiolitis Obliterans1